Ipca Laboratories Croissance future
Future contrôle des critères 2/6
Ipca Laboratories devrait augmenter ses bénéfices et son chiffre d'affaires de 17.3% et de 10.5% par an respectivement. Le BPA devrait croître de de 17.3% par an. Le rendement des capitaux propres devrait être 15.8% dans 3 ans.
Informations clés
17.3%
Taux de croissance des bénéfices
17.27%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 18.1% |
| Taux de croissance des recettes | 10.5% |
| Rendement futur des capitaux propres | 15.82% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 17 Jul 2026 |
Mises à jour récentes de la croissance future
Article d’analyse • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Article d’analyse • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...Article d’analyse • Jun 01
Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Ipca Laboratories Limited ( NSE:IPCALAB ) released its yearly result to the market...Article d’analyse • Feb 16
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders might have noticed that Ipca Laboratories Limited ( NSE:IPCALAB ) filed its third-quarter result this time...Recent updates
Mise à jour du récit • Jul 17
IPCALAB: Board Reviews And Merger Plan Will Shape Measured Upside Potential
The analyst price target for Ipca Laboratories has shifted from ₹1,887 to about ₹1,968, with analysts linking this change to updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Ipca Laboratories has scheduled a board meeting on May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026, and to consider a dividend recommendation for the 2025-26 financial year.
Mise à jour du récit • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.
Mise à jour du récit • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Mise à jour du récit • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Article d’analyse • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Mise à jour du récit • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).Mise à jour du récit • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Mise à jour du récit • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).Mise à jour du récit • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.Mise à jour du récit • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).Mise à jour du récit • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.Article d’analyse • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Article d’analyse • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Mise à jour du récit • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.Mise à jour du récit • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Article d’analyse • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Mise à jour du récit • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.Mise à jour du récit • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).Mise à jour du récit • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.Article d’analyse • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Mise à jour du récit • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.Mise à jour du récit • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.Article d’analyse • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...Article d’analyse • Sep 05
If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...Article d’analyse • Jul 08
Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...Article d’analyse • Jun 24
Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Ipca Laboratories Limited ( NSE:IPCALAB ) will pay a dividend of ₹2.00 on the 1st of January. This payment means the...Article d’analyse • Jun 01
Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Last week, you might have seen that Ipca Laboratories Limited ( NSE:IPCALAB ) released its yearly result to the market...Article d’analyse • May 22
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 51.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Article d’analyse • Feb 16
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders might have noticed that Ipca Laboratories Limited ( NSE:IPCALAB ) filed its third-quarter result this time...Article d’analyse • Jan 10
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Dec 20
Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
With a price-to-earnings (or "P/E") ratio of 61.2x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...
Nouveau récit • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Article d’analyse • Nov 17
Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
The board of Ipca Laboratories Limited ( NSE:IPCALAB ) has announced that it will pay a dividend of ₹2.00 per share on...Article d’analyse • Sep 10
Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Ipca Laboratories Limited's ( NSE:IPCALAB ) price-to-earnings (or "P/E") ratio of 61.7x might make it look like a...Article d’analyse • Jun 07
Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Ipca Laboratories Limited ( NSE:IPCALAB ) recently...Article d’analyse • May 24
Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 31x, you may consider Ipca...Article d’analyse • Feb 07
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
With a price-to-earnings (or "P/E") ratio of 61.8x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Article d’analyse • Jan 09
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Aug 20
Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Feb 28
Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2029 | 132,985 | 19,471 | 14,641 | 20,073 | 5 |
| 3/31/2028 | 120,078 | 16,697 | 10,997 | 17,079 | 14 |
| 3/31/2027 | 107,687 | 14,000 | 9,492 | 14,590 | 16 |
| 3/31/2026 | 96,472 | 11,411 | 4,860 | 11,420 | N/A |
| 12/31/2025 | 95,062 | 9,099 | N/A | N/A | N/A |
| 9/30/2025 | 93,590 | 8,317 | 4,697 | 13,618 | N/A |
| 6/30/2025 | 91,574 | 7,787 | N/A | N/A | N/A |
| 3/31/2025 | 89,412 | 7,377 | 5,458 | 13,213 | N/A |
| 12/31/2024 | 87,268 | 7,295 | N/A | N/A | N/A |
| 9/30/2024 | 85,343 | 6,612 | 8,970 | 14,414 | N/A |
| 6/30/2024 | 82,133 | 5,768 | N/A | N/A | N/A |
| 3/31/2024 | 77,059 | 5,474 | 5,334 | 9,447 | N/A |
| 12/31/2023 | 71,875 | 5,643 | N/A | N/A | N/A |
| 9/30/2023 | 66,806 | 4,922 | 2,606 | 6,767 | N/A |
| 6/30/2023 | 62,500 | 4,911 | N/A | N/A | N/A |
| 3/31/2023 | 62,481 | 4,713 | 3,113 | 8,058 | N/A |
| 12/31/2022 | 60,225 | 5,250 | N/A | N/A | N/A |
| 9/30/2022 | 59,070 | 6,142 | 2,398 | 7,616 | N/A |
| 6/30/2022 | 58,505 | 7,205 | N/A | N/A | N/A |
| 3/31/2022 | 58,305 | 8,841 | 3,771 | 8,561 | N/A |
| 12/31/2021 | 56,561 | 9,152 | N/A | N/A | N/A |
| 9/30/2021 | 56,355 | 9,837 | 3,728 | 8,554 | N/A |
| 6/30/2021 | 54,521 | 10,005 | N/A | N/A | N/A |
| 3/31/2021 | 54,207 | 11,400 | 7,286 | 10,901 | N/A |
| 12/31/2020 | 53,802 | 10,647 | N/A | N/A | N/A |
| 9/30/2020 | 51,833 | 9,968 | 7,371 | 10,767 | N/A |
| 6/30/2020 | 51,061 | 9,228 | N/A | N/A | N/A |
| 3/31/2020 | 46,499 | 6,063 | 2,641 | 5,704 | N/A |
| 12/31/2019 | 44,563 | 6,189 | N/A | N/A | N/A |
| 9/30/2019 | 42,496 | 5,804 | N/A | 5,181 | N/A |
| 6/30/2019 | 39,777 | 5,059 | N/A | N/A | N/A |
| 3/31/2019 | 37,750 | 4,448 | N/A | 5,010 | N/A |
| 3/31/2018 | 32,852 | 2,394 | N/A | 3,411 | N/A |
| 3/31/2017 | 31,562 | 1,945 | N/A | 2,819 | N/A |
| 3/31/2016 | 28,671 | 931 | N/A | 7,087 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de IPCALAB ( 17.3% par an) est supérieure au taux d'épargne ( 6.9% ).
Bénéfices vs marché: Les bénéfices de IPCALAB ( 17.3% par an) devraient croître plus rapidement que le marché Indian ( 16.6% par an).
Croissance élevée des bénéfices: Les bénéfices de IPCALAB devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de IPCALAB ( 10.5% par an) devrait croître plus lentement que le marché de Indian ( 11% par an).
Croissance élevée des revenus: Le chiffre d'affaires de IPCALAB ( 10.5% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de IPCALAB devrait être faible dans 3 ans ( 15.8 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/13 18:50 |
| Cours de l'action en fin de journée | 2026/08/13 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Ipca Laboratories Limited est couverte par 38 analystes. 16 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |